Immune Response News and Research

RSS

Cancer triggers scleroderma, shows evidence

Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.

6 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

"Virtual T cell" predicts how human immune system reacts to foreign substances

A platform that simulates how the body defends itself: The T cells of the immune system decide whether to trigger an immune response against foreign substances.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

For some, the disease multiple sclerosis attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages-even before the onset of physical signs.

3 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

Research proves effectiveness of vaccine against leishmaniasis

The disease is considered endemic in the south states of Mexico. A research executed in the Autonomous University of Yucatan (UADY) has successfully proved, in test animals, the effectiveness of a vaccine that immunizes the organism against leishmaniasis, an ailment transmitted through insects very similar to mosquitos and mainly presents symptoms in the skin, liver or spleen.

3 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

Childhood asthma, eczema linked to adolescent psychotic experiences

UK research indicates that children with asthma and eczema are significantly more likely to have psychotic experiences during adolescence, boosting a previously reported relationship between schizophrenia and atopic disorders.

28 Nov 2013

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge. However, it did not lead to significant changes in hay fever symptoms, although this challenge test may not have accurately represented natural allergen exposure.

27 Nov 2013

European research project examines toxicity factor to fight AIDS

December 1st is the annual World AIDS Day, a perfect opportunity to look at how medical research is progressing to fight the disease.

27 Nov 2013

WHO releases new treatment guidelines for children suffering severe acute malnutrition

WHO today released new treatment guidelines for the almost 20 million children under-five worldwide who have severe acute malnutrition.

27 Nov 2013

Inhibition of complement system plays major role in xenograft rejection

Researchers at the Bellvitge Institute of Biomedical Research (IDIBELL) led by Cristina Costa from the New Therapies on Genes and Transplantation group have shown that inhibition of one of the basic components of the complement system protects chondrocytes (cartilage cells) from porcine rejection of xenotransplantation (transplantation between animals of different species).

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

EU-funded project develops new type of vaccine to tackle HIV virus infection

AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41, is based on one of the envelope proteins of the HIV virus, called the gp41 protein. What makes it interesting it that it is directly responsible for the fusion of the HIV virus into human cells. By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells

27 Nov 2013

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes - which play a central role in the body's immune response - with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA).

26 Nov 2013

Immune Response News and Research

Cancer triggers scleroderma, shows evidence

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

"Virtual T cell" predicts how human immune system reacts to foreign substances

New method for counting tumor-fighting cells to predict ovarian cancer

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers offer promise of strategy for curing HIV infection

Research proves effectiveness of vaccine against leishmaniasis

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

Childhood asthma, eczema linked to adolescent psychotic experiences

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

European research project examines toxicity factor to fight AIDS

WHO releases new treatment guidelines for children suffering severe acute malnutrition

Inhibition of complement system plays major role in xenograft rejection

UMass Medical School licenses "anti-gal" technology to Agalimmune

EU-funded project develops new type of vaccine to tackle HIV virus infection

Researchers successfully target T lymphocytes which play key role in body's immune response

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News